907 related articles for article (PubMed ID: 28596286)
1. One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration.
Braimah IZ; Agarwal K; Mansour A; Chhablani J;
Br J Ophthalmol; 2018 Jan; 102(1):91-96. PubMed ID: 28596286
[TBL] [Abstract][Full Text] [Related]
2. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
Park DH; Sun HJ; Lee SJ
Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
[TBL] [Abstract][Full Text] [Related]
3. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.
Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P
BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756
[TBL] [Abstract][Full Text] [Related]
4. High-frequency aflibercept injections in persistent neovascular age-related macular degeneration.
Muftuoglu IK; Tsai FF; Gaber R; Alam M; Meshi A; Freeman WR
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):709-717. PubMed ID: 27878592
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
[TBL] [Abstract][Full Text] [Related]
6. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
Jørstad ØK; Faber RT; Moe MC
Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485
[TBL] [Abstract][Full Text] [Related]
7. Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy.
Singh SR; Sahoo NK; Goud NR; Chhablani J
Indian J Ophthalmol; 2019 Jul; 67(7):1114-1118. PubMed ID: 31238423
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal ziv-aflibercept for the treatment of choroidal neovascularisation associated with conditions other than age-related macular degeneration.
Braimah IZ; Stewart M; Videkar C; Dedhia CJ; Chhablani J;
Br J Ophthalmol; 2017 Sep; 101(9):1201-1205. PubMed ID: 28119292
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Eyes Lost to Follow-up with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Anti-Vascular Endothelial Growth Factor.
Soares RR; Mellen P; Garrigan H; Obeid A; Wibbelsman TD; Borkar D; Ho AC; Hsu J
Ophthalmol Retina; 2020 Feb; 4(2):134-140. PubMed ID: 31540854
[TBL] [Abstract][Full Text] [Related]
10. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of switching to aflibercept for treatment-resistant neovascular age-related macular degeneration.
Spooner K; Hong T; Nair R; Chow NCC; Broadhead GK; Wijeyakumar W; Chang AA
Acta Ophthalmol; 2019 Aug; 97(5):e706-e712. PubMed ID: 30740921
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab dosing every 2 weeks for neovascular age-related macular degeneration refractory to monthly dosing.
Mimouni M; Meshi A; Vainer I; Gershoni A; Koren T; Geffen N; Nemet AY; Segal O
Jpn J Ophthalmol; 2018 Nov; 62(6):652-658. PubMed ID: 30269186
[TBL] [Abstract][Full Text] [Related]
13. Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration.
Messenger WB; Campbell JP; Faridi A; Shippey L; Bailey ST; Lauer AK; Flaxel CJ; Hwang TS
Br J Ophthalmol; 2014 Sep; 98(9):1205-7. PubMed ID: 24795334
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes.
Gharbiya M; Giustolisi R; Marchiori J; Bruscolini A; Mallone F; Fameli V; Nebbioso M; Abdolrahimzadeh S
Curr Eye Res; 2018 Mar; 43(3):391-396. PubMed ID: 29166140
[TBL] [Abstract][Full Text] [Related]
15. Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results.
Homer N; Grewal DS; Mirza RG; Lyon AT; Gill MK
Eye (Lond); 2015 Sep; 29(9):1152-5. PubMed ID: 26021870
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal Ziv-Aflibercept : Safety Analysis in Eyes Receiving More Than Ten Intravitreal Injections.
Singh SR; Chattannavar G; Ayachit A; Pimentel MC; Alfaro A; Tiwari S; Heranjal A; Subramanyam A; Braimah IZ; Dhami A; Sachdev P; Mansour A; Chhablani J
Semin Ophthalmol; 2020 Jan; 35(1):2-6. PubMed ID: 31690175
[No Abstract] [Full Text] [Related]
17. Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration.
Abdin AD; Suffo S; Asi F; Langenbucher A; Seitz B
Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1671-1677. PubMed ID: 31144055
[TBL] [Abstract][Full Text] [Related]
18. Baseline Optical Coherence Tomography Findings as Outcome Predictors after Switching from Ranibizumab to Aflibercept in Neovascular Age-Related Macular Degeneration following a Treat-and-Extend Regimen.
Türksever C; Prünte C; Hatz K
Ophthalmologica; 2017; 238(3):172-178. PubMed ID: 28772268
[TBL] [Abstract][Full Text] [Related]
19. Two-year outcomes of intravitreal ziv-aflibercept.
Mansour AM; Ashraf M; Charbaji A; Younis MH; Souka AA; Dogra A; Mansour HA; Chhablani J;
Br J Ophthalmol; 2018 Oct; 102(10):1387-1390. PubMed ID: 29317400
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy.
Ogasawara M; Koizumi H; Yamamoto A; Itagaki K; Saito M; Maruko I; Okada AA; Iida T; Sekiryu T
Jpn J Ophthalmol; 2018 Sep; 62(5):584-591. PubMed ID: 29974277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]